Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5

Molecules and Cells

Volumn 35, Issue 1, 2013, Pages 32-40

  Kim, Eun Young ^a   Yu, Ji Sun ^a   Yang, Mihi ^a   Kim, An Keun ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

apigenin; apoptosis; DR5; ERK; HepG2; TRAIL

Indexed keywords

APIGENIN; CASPASE INHIBITOR; DEATH RECEPTOR 5; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL STRAIN HEPG2; CELL STRUCTURE; CELL SURFACE; CELL VIABILITY; CHIMERA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SENSITIZATION; SIGNAL TRANSDUCTION;

APIGENIN; APOPTOSIS; BLOTTING, WESTERN; BUTADIENES; CASPASES; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HEP G2 CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRILES; POLY(ADP-RIBOSE) POLYMERASES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84872839183     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.1007/s10059-013-2175-2     Document Type: Article

References (45)

1. Ashkenazi, A. (2002). Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2, 420-430.
2. Chen, C.Y.; Tai, C.J.; Cheng, J.T.; Zheng, J.J.; Chen, Y.Z.; Liu, T.Z.; Yiin, S.J.; and Chern, C.L. (2010). 6-dehydrogingerdione sensitizes human hepatoblastoma Hep G2 cells to TRAIL-induced apoptosis via reactive oxygen species-mediated increase of DR5. J. Agric. Food Chem. 58, 5604-5611.
3. Choi, S.; Jeong, C.; Cho, S.; and Lee, Y. (2007). Mechanism of apoptosis induced by apigenin in hepg2 human hepatoma cells: involvement of reactive oxygen species generated by NADPH oxidase. Arch. Pharm. Res. 30, 1328-1335.
4. Cohen, G.M. (1997). Caspases: the executioners of apoptosis. Biochem. J. 326, 1-16.
5. Cuzick, J.; Stewart, H.; Rutqvist, L.; Houghton, J.; Edwards, R.; Redmond, C.; Peto, R.; Baum, M.; Fisher, B.; Host, H.; et al. (1994). Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J. Clin. Oncol. 12, 447-453.
6. Czeczot, H.; Tudek, B.; Kusztelak, J.; Szymczyk, T.; Dobrowolska, B.; Glinkowska, G.; Malinowski, J.; and Strzelecka, H. (1990). Isolation and studies of the mutagenic activity in the Ames test of flavonoids naturally occurring in medical herbs. Mutat. Res. 240, 209-216.
7. Degli-Esposti, M.A.; Dougall, W.C.; Smolak, P.J.; Waugh, J.Y.; Smith, C.A.; and Goodwin, R.G. (1997). The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7, 813-820.
8. Drosopoulos, K.G.; Roberts, M.L.; Cermak, L.; Sasazuki, T.; Shirasawa, S.; Andera, L.; and Pintzas, A. (2005). Transformation by oncogenic RAS sensitizes human colon cells to TRAILinduced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J. Biol. Chem. 280, 22856-22867.
9. Fan, T.-J.; Han, L.-H.; Cong, R.-S.; and Liang, J. (2005). Caspase family proteases and apoptosis. Acta Biochem. Biophys. Sin. 37, 719-727.
10. Gupta, S.; Afaq, F.; and Mukhtar, H. (2001). Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem. Biophys. Res. Commun. 287, 914-920.
11. Gupta, S.C.; Reuter, S.; Phromnoi, K.; Park, B.; Hema, P.S.; Nair, M.; and Aggarwal, B.B. (2011). Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax. J. Biol. Chem. 286, 1134-1146.
12. Häcker, G. (2000). The morphology of apoptosis. Cell Tissue Res. 301, 5-17.
13. He, S.; Chen, Y.; Chen, X.; Zhao, Y.; Wang, H.; Zhang, W.; and Wang, S. (2005). Antitumor effects of soluble TRAIL in human hepatocellular carcinoma. J. Huazhong Univ. Sci. Technol. Med. Sci. 25, 51-54.
14. Horinaka, M.; Yoshida, T.; Shiraishi, T.; Nakata, S.; Wakada, M.; and Sakai, T. (2006). The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosisinducing ligand. Mol. Cancer Ther. 5, 945-951.
15. Jalving, M.; Koornstra, J.J.; De Jong, S.; De Vries, E.G.; and Kleibeuker, J.H. (2005). Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment. Pharm. Ther. 21, 321-339.
16. Kang, C.H.; Moon, D.O.; Choi, Y.H.; Choi, I.W.; Moon, S.K.; Kim, W.J.; and Kim, G.Y. (2011). Piceatannol enhances TRAIL-induced apoptosis in human leukemia THP-1 cells through Sp1- and ERK-dependent DR5 up-regulation. Toxicol. In Vitro 25, 605-612.
17. Kasibhatla, S.; and Tseng, B. (2003). Why target apoptosis in cancer treatment? Mol. Cancer Ther. 2, 573-580.
18. Kim, Y.; and Seol, D.W. (2003). TRAIL, a mighty apoptosis inducer. Mol. Cells 15, 283-293.
19. Kruyt, F.A.E. (2008). TRAIL and cancer therapy. Cancer Lett. 263, 14-25.
20. Kumar, S. (2007). Caspase function in programmed cell death. Cell Death Differ. 14, 32-43.
21. Lu, G.; Liu, Y.; Ji, B.; Wei, F.; Hao, C.; and Wang, G. (2010). Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells. Cancer Invest. 28, 629-634.
22. Mahalingam, D.; Szegezdi, E.; Keane, M.; de Jong, S.; and Samali, A. (2009). TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat. Rev. 35, 280-288.
23. Malhi, H.; and Gores, G.J. (2006). TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 25, 7333-7335.
24. Moon, D.O.; Kim, M.O.; Choi, Y.H.; and Kim, G.Y. (2010). Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation. Mol. Cancer Ther. 9, 1583-1595.
25. Nakshatri, H.; Rice, S.E.; and Bhat-Nakshatri, P. (2004). Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23, 7330-7344.
26. Pan, G.; Ni, J.; Wei, Y.F.; Yu, G.; Gentz, R.; and Dixit, V.M. (1997a). An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277, 815-818.
27. Pan, G.; O'Rourke, K.; Chinnaiyan, A.M.; Gentz, R.; Ebner, R.; Ni, J.; and Dixit, V.M. (1997b). The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113.
28. Prasad, S.; Yadav, V.R.; Kannappan, R.; and Aggarwal, B.B. (2011). Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK. J. Biol. Chem. 286, 5546-5557.
29. Redding, S.W. (2005). Cancer therapy-related oral mucositis. J. Dent. Educ. 69, 919-929.
30. Rupnow, B.A.; and Knox, S.J. (1999). The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. Apoptosis 4, 115-143.
31. Russo, A.; Terrasi, M.; Agnese, V.; Santini, D.; and Bazan, V. (2006). Apoptosis: a relevant tool for anticancer therapy. Ann. Oncol. 17Suppl 7, vii115-123.
32. Shigeno, M.; Nakao, K.; Ichikawa, T.; Suzuki, K.; Kawakami, A.; Abiru, S.; Miyazoe, S.; Nakagawa, Y.; Ishikawa, H.; Hamasaki, K.; et al. (2003). Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NFkappa B inactivation. Oncogene 22, 1653-1662.
33. Shukla, S.; and Gupta, S. (2006). Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol. Cancer Ther. 5, 843-852.
34. Simon, H.U.; Haj-Yehia, A.; and Levi-Schaffer, F. (2000). Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5, 415-418.
35. Sung, B.; Ravindran, J.; Prasad, S.; Pandey, M.K.; and Aggarwal, B.B. (2010). Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J. Biol. Chem. 285, 35418-35427.
36. van Engeland, M.; Nieland, L.J.; Ramaekers, F.C.; Schutte, B.; and Reutelingsperger, C.P. (1998). Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31, 1-9.
37. van Noesel, M.M.; van Bezouw, S.; Salomons, G.S.; Voute, P.A.; Pieters, R.; Baylin, S.B.; Herman, J.G.; and Versteeg, R. (2002). Tumor-specific down-regulation of the tumor necrosis factorrelated apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res. 62, 2157-2161.
38. Wada, T.; and Penninger, J.M. (2004). Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23, 2838-2849.
39. Walczak, H.; and Krammer, P.H. (2000). The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 256, 58-66.
40. Walczak, H.; Degli-Esposti, M.A.; Johnson, R.S.; Smolak, P.J.; Waugh, J.Y.; Boiani, N.; Timour, M.S.; Gerhart, M.J.; Schooley, K.A.; Smith, C.A.; et al. (1997). TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16, 5386-5397.
41. Xu, L.; Zhang, L.; Bertucci, A.M.; Pope, R.M.; and Datta, S.K. (2008). Apigenin, a dietary flavonoid, sensitizes human T cells for activation-induced cell death by inhibiting PKB/Akt and NFkappaB activation pathway. Immunol. Lett. 121, 74-83.
42. Xu, Y.; Xin, Y.; Diao, Y.; Lu, C.; Fu, J.; Luo, L.; and Yin, Z. (2011). Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells. PLoS One 6, e29169.
43. Yang, Y.; Zhao, S.; and Song, J. (2004). Caspase-dependent apoptosis and -independent poly (ADP-ribose) polymerase cleavage induced by transforming growth factor beta1. Int. J. Biochem. Cell Biol. 36, 223-234.
44. Yodkeeree, S.; Sung, B.; Limtrakul, P.; and Aggarwal, B.B. (2009). Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: evidence for an essential role of reactive oxygen species. Cancer Res. 69, 6581-6589.
45. Zhang, L.; and Fang, B. (2004). Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12, 228-237.